Date: 2017-02-07
Type of
information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Abbvie (USA - IL)
Product: risankizumab
Action
mechanism:
- monoclonal antibody. Risankizumab selectively blocks IL-23, a key protein involved in inflammatory processes that has been linked to a number of chronic immune-mediated diseases. Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading future development and commercialization of risankizumab globally. The therapeutic potential of risankizumab is being evaluated in immunological disorders, including Crohn’s disease, psoriasis, and psoriatic arthritis.
Disease: psoriasis
Therapeutic
area: Autoimmune diseases - Dermatological diseases
Country: Canada, USA
Trial
details:
- LIMMITLESS is a multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis. (NCT03047395)
Latest
news:
- • On February 7, 2017, a Phase 3 trial sponsored by Abbvie was published on the NIH website ClinicalTrials.gov for risankizumab and is currently recruiting participants.
Is
general: Yes
